deferoxamine has been researched along with Body Weight in 45 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats." | 7.75 | Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009) |
| "A single subcutaneous dose of 30 nmol of sodium selenite per gram of body weight in 13-day-old rats resulted in posterior subcapsular cataract (PSC) after 24 hr and bilateral nuclear cataracts at 72-96 hr." | 7.68 | Deferoxamine effect on selenite-induced cataract formation in rats. ( Bunce, GE; Hess, JL; Wang, Z, 1992) |
| "The present work deals with the effect of desferrioxamine (DF) on hexachlorobenzene (HCB)-induced porphyria in female rats with the purpose of further investigation of the role of iron in the development of this porphyria." | 7.67 | Effect of desferrioxamine on the development of hexachlorobenzene-induced porphyria. ( Aldonatti, CA; Billi, SC; San Martín de Viale, LC; Wainstock de Calmanovici, R, 1986) |
| " Based on evidence that excess iron may increase oxidative stress and contribute to the inflammatory response, we investigated whether deferoxamine (DFX), a potent iron chelating agent, reduces oxidative stress and inflammation in the diaphragm (DIA) muscle of mdx mice (an experimental model of DMD)." | 3.81 | Reduction of Oxidative Damage and Inflammatory Response in the Diaphragm Muscle of mdx Mice Using Iron Chelator Deferoxamine. ( de Almeida Hermes, T; de Burgos, RR; de Faria, FM; Macedo, AB; Minatel, E; Moraes, LH, 2015) |
| "Deferoxamine (DFX) reduces brain edema, neuronal death, and neurological deficits after intracerebral hemorrhage (ICH) in young rats." | 3.75 | Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. ( Hua, Y; Keep, RF; Morgenstern, LB; Okauchi, M; Xi, G, 2009) |
| "A single subcutaneous dose of 30 nmol of sodium selenite per gram of body weight in 13-day-old rats resulted in posterior subcapsular cataract (PSC) after 24 hr and bilateral nuclear cataracts at 72-96 hr." | 3.68 | Deferoxamine effect on selenite-induced cataract formation in rats. ( Bunce, GE; Hess, JL; Wang, Z, 1992) |
| "An ovine model of maternal iron poisoning in pregnancy was used to examine the placental transport of deferoxamine and ferrioxamine and to follow maternal and fetal serum iron concentrations when maternal serum iron levels exceeded total iron-binding capacity." | 3.68 | An ovine model of maternal iron poisoning in pregnancy. ( Bond, GR; Curry, SC; Raschke, R; Tellez, D; Wiggins, D, 1990) |
| "The present work deals with the effect of desferrioxamine (DF) on hexachlorobenzene (HCB)-induced porphyria in female rats with the purpose of further investigation of the role of iron in the development of this porphyria." | 3.67 | Effect of desferrioxamine on the development of hexachlorobenzene-induced porphyria. ( Aldonatti, CA; Billi, SC; San Martín de Viale, LC; Wainstock de Calmanovici, R, 1986) |
| "Quercetin has been demonstrated to quench production of intracellular free iron-induced -OH, but the effect of quercetin in ethanol-induced cardiac damage remains unclear." | 1.48 | Quercetin Attenuates Ethanol-Induced Iron Uptake and Myocardial Injury by Regulating the Angiotensin II-L-Type Calcium Channel. ( Chen, M; Dong, Z; Gao, C; Guo, X; Liu, J; Liu, P; Tang, Y; Yao, P; Zeng, H; Zhang, J; Zhou, F; Zhu, X, 2018) |
| "Asbestos-induced mesothelial carcinogenesis is currently a profound social issue due to its extremely long incubation period and high mortality rate." | 1.43 | Dual preventive benefits of iron elimination by desferal in asbestos-induced mesothelial carcinogenesis. ( Akatsuka, S; Chew, SH; Jiang, L; Nakamura, K; Ohara, Y; Toyokuni, S, 2016) |
| "Intracerebral hemorrhage was induced by intrastriatal injection of collagenase." | 1.37 | Iron toxicity in mice with collagenase-induced intracerebral hemorrhage. ( Wang, J; Wu, H; Wu, T; Xu, X, 2011) |
| " This study supports the idea that iron and free radicals play a critical role in the toxic side effects of aminoglycoside antibiotics." | 1.30 | Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity. ( Schacht, J; Sha, SH; Song, BB, 1998) |
| " Desferrioxamine at this dosage did not retard growth." | 1.26 | Experimental anemia induced by excess iron excretion. ( Ishibashi, K; Kimura, I; Matsuzaka, H; Miyata, A; Sugiyama, M, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (31.11) | 18.7374 |
| 1990's | 13 (28.89) | 18.2507 |
| 2000's | 9 (20.00) | 29.6817 |
| 2010's | 8 (17.78) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 1 |
| Wu, Z | 1 |
| Lan, H | 1 |
| Chen, S | 1 |
| Wu, J | 1 |
| Zhu, L | 1 |
| Xiao, Y | 1 |
| Guo, X | 1 |
| Chen, M | 2 |
| Zeng, H | 1 |
| Liu, P | 1 |
| Zhu, X | 1 |
| Zhou, F | 1 |
| Liu, J | 1 |
| Zhang, J | 2 |
| Dong, Z | 1 |
| Tang, Y | 2 |
| Gao, C | 1 |
| Yao, P | 2 |
| Moraes, LH | 1 |
| de Burgos, RR | 1 |
| Macedo, AB | 1 |
| de Almeida Hermes, T | 1 |
| de Faria, FM | 1 |
| Minatel, E | 1 |
| Li, Y | 1 |
| Xu, Y | 1 |
| Yu, X | 1 |
| Xiong, T | 1 |
| Du, M | 1 |
| Sun, J | 1 |
| Liu, L | 1 |
| Jiang, L | 1 |
| Chew, SH | 1 |
| Nakamura, K | 1 |
| Ohara, Y | 1 |
| Akatsuka, S | 1 |
| Toyokuni, S | 1 |
| Xue, H | 1 |
| Chen, D | 1 |
| Zhong, YK | 1 |
| Zhou, ZD | 1 |
| Fang, SX | 1 |
| Li, MY | 1 |
| Guo, C | 1 |
| Tubafard, S | 1 |
| Fatemi, SJ | 2 |
| Larosche, I | 1 |
| Choumar, A | 1 |
| Fromenty, B | 1 |
| Lettéron, P | 1 |
| Abbey-Toby, A | 1 |
| Van Remmen, H | 1 |
| Epstein, CJ | 1 |
| Richardson, A | 1 |
| Feldmann, G | 1 |
| Pessayre, D | 1 |
| Mansouri, A | 1 |
| Okauchi, M | 1 |
| Hua, Y | 1 |
| Keep, RF | 1 |
| Morgenstern, LB | 1 |
| Xi, G | 1 |
| Sinis, N | 1 |
| Di Scipio, F | 1 |
| Schönle, P | 1 |
| Werdin, F | 1 |
| Kraus, A | 1 |
| Koopmanns, G | 1 |
| Masanneck, C | 1 |
| Hermanns, S | 1 |
| Danker, T | 1 |
| Guenther, E | 1 |
| Haerle, M | 1 |
| Schaller, HE | 1 |
| Geuna, S | 1 |
| Mueller, HW | 1 |
| Wu, H | 1 |
| Wu, T | 1 |
| Xu, X | 1 |
| Wang, J | 2 |
| Langlois, A | 1 |
| Bietiger, W | 1 |
| Seyfritz, E | 1 |
| Maillard, E | 1 |
| Vivot, K | 1 |
| Peronet, C | 1 |
| Meyer, N | 1 |
| Kessler, L | 1 |
| Jeandidier, N | 1 |
| Pinget, M | 1 |
| Sigrist, S | 1 |
| Saljooghi, AS | 1 |
| Balooch, FD | 1 |
| Iranmanesh, M | 1 |
| Golbafan, MR | 1 |
| Simonart, T | 1 |
| Boelaert, JR | 1 |
| Andrei, G | 1 |
| van den Oord, JJ | 1 |
| Degraef, C | 1 |
| Hermans, P | 1 |
| Noel, JC | 1 |
| Van Vooren, JP | 1 |
| Heenen, M | 1 |
| De Clercq, E | 1 |
| Snoeck, R | 1 |
| Leikin, S | 1 |
| Vossough, P | 1 |
| Mochir-Fatemi, F | 1 |
| Kimura, I | 1 |
| Sugiyama, M | 1 |
| Ishibashi, K | 1 |
| Miyata, A | 1 |
| Matsuzaka, H | 1 |
| Melograna, JM | 1 |
| Yokel, RA | 1 |
| Lindnér, P | 1 |
| Naredi, P | 1 |
| Peterson, A | 1 |
| Hafström, L | 1 |
| Meulenbelt, J | 1 |
| Dormans, JA | 1 |
| van Bree, L | 1 |
| Rombout, PJ | 1 |
| Sangster, B | 1 |
| Herman, EH | 1 |
| Ferrans, VJ | 1 |
| Bosque, MA | 1 |
| Domingo, JL | 2 |
| Corbella, J | 2 |
| Nagler, R | 1 |
| Marmary, Y | 1 |
| Golan, E | 1 |
| Chevion, M | 1 |
| Song, BB | 1 |
| Sha, SH | 1 |
| Schacht, J | 1 |
| Belles, M | 1 |
| Gomez, M | 1 |
| Sanchez, DJ | 1 |
| Mayayo, E | 1 |
| Moos, T | 1 |
| Morgan, EH | 1 |
| Kuvibidila, SR | 1 |
| Kitchens, D | 1 |
| Baliga, BS | 1 |
| Karasu, C | 1 |
| El-Khatib, AS | 1 |
| Moustafa, AM | 1 |
| Abdel-Aziz, AA | 1 |
| Al-Shabanah, OA | 1 |
| El-Kashef, HA | 1 |
| Nagler, RM | 1 |
| Eichen, Y | 1 |
| Nagler, A | 1 |
| Viprakasit, V | 1 |
| Tanphaichitr, VS | 1 |
| Mahasandana, C | 1 |
| Assteerawatt, A | 1 |
| Suwantol, L | 1 |
| Veerakul, G | 1 |
| Kankirawatana, S | 1 |
| Pung-Amritt, P | 1 |
| Suvatte, V | 1 |
| Wang, Z | 1 |
| Hess, JL | 1 |
| Bunce, GE | 1 |
| Hann, HW | 1 |
| Stahlhut, MW | 1 |
| Rubin, R | 1 |
| Maddrey, WC | 1 |
| Curry, SC | 1 |
| Bond, GR | 1 |
| Raschke, R | 1 |
| Tellez, D | 1 |
| Wiggins, D | 1 |
| Wahba, ZZ | 1 |
| Murray, WJ | 1 |
| Stohs, SJ | 1 |
| Cross, CE | 1 |
| Warren, D | 1 |
| Gerriets, JE | 1 |
| Wilson, DW | 1 |
| Halliwell, B | 1 |
| Last, JA | 1 |
| Cutler, P | 1 |
| Wainstock de Calmanovici, R | 1 |
| Billi, SC | 1 |
| Aldonatti, CA | 1 |
| San Martín de Viale, LC | 1 |
| Longueville, A | 1 |
| Crichton, RR | 1 |
| Kim, BK | 1 |
| Huebers, H | 1 |
| Pippard, MJ | 1 |
| Finch, CA | 1 |
| Bohne, F | 1 |
| Harmuth-Hoene, AE | 1 |
| Weber, KM | 1 |
| Chvapil, M | 1 |
| McCarthy, D | 1 |
| Madden, JW | 1 |
| Peacock, EE | 1 |
| Graziano, JH | 1 |
| Grady, RW | 1 |
| Cerami, A | 1 |
| Wolff, JA | 1 |
| Luke, KH | 1 |
| Hofvander, Y | 1 |
| Hitier, Y | 1 |
| Terroine, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895] | Phase 2 | 42 participants (Actual) | Interventional | 2013-03-18 | Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 3 |
| Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 1 |
| Normal Saline | 1 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 0 |
| Normal Saline | 1 |
(NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 9 |
| Normal Saline | 6 |
(NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 6 |
| Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 0 |
| Normal Saline | 0 |
"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 6 |
| Normal Saline | 10 |
The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 12 |
| Normal Saline | 14 |
45 other studies available for deferoxamine and Body Weight
| Article | Year |
|---|---|
[Deferoxamine promotes recovery of bone marrow hematopoietic function in mice exposed to a sublethal dose of X-ray irradiation].
Topics: Animals; Body Weight; Bone Marrow; Bone Marrow Cells; Caspase 3; Deferoxamine; Mice; Poly(ADP-ribose | 2023 |
Quercetin Attenuates Ethanol-Induced Iron Uptake and Myocardial Injury by Regulating the Angiotensin II-L-Type Calcium Channel.
Topics: Angiotensin II; Animals; Body Weight; Calcium Channels, L-Type; Deferoxamine; Ethanol; Heart; Iron; | 2018 |
Reduction of Oxidative Damage and Inflammatory Response in the Diaphragm Muscle of mdx Mice Using Iron Chelator Deferoxamine.
Topics: Animals; Blotting, Western; Body Weight; Deferoxamine; Diaphragm; Female; Inflammation; Injections, | 2015 |
Iron-Mediated Lysosomal Membrane Permeabilization in Ethanol-Induced Hepatic Oxidative Damage and Apoptosis: Protective Effects of Quercetin.
Topics: Animals; Apoptosis; Body Weight; Deferoxamine; Dietary Supplements; Ethanol; Feeding Behavior; Hepat | 2016 |
Dual preventive benefits of iron elimination by desferal in asbestos-induced mesothelial carcinogenesis.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Asbestos; Body Weight; Carcinogenesis; Cell Proliferation; Def | 2016 |
Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice.
Topics: Animals; Apoptosis Regulatory Proteins; Body Weight; Deferoxamine; Feeding Behavior; Gene Expression | 2016 |
Chelation of bismuth by combining desferrioxamine and deferiprone in rats.
Topics: Animals; Bismuth; Body Weight; Chelation Therapy; Deferiprone; Deferoxamine; Drug Therapy, Combinati | 2008 |
Prolonged ethanol administration depletes mitochondrial DNA in MnSOD-overexpressing transgenic mice, but not in their wild type littermates.
Topics: Alcohol Drinking; Animals; Body Weight; Caspase 3; Catalase; Cytochrome P-450 CYP2E1; Deferoxamine; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats.
Topics: Animals; Atrophy; Behavior, Animal; Blood Pressure; Body Water; Body Weight; Brain; Brain Diseases; | 2009 |
Local administration of DFO-loaded lipid particles improves recovery after end-to-end reconstruction of rat median nerve.
Topics: Analysis of Variance; Animals; Body Weight; Deferoxamine; Disease Models, Animal; Electric Stimulati | 2009 |
Iron toxicity in mice with collagenase-induced intracerebral hemorrhage.
Topics: Animals; Body Weight; Cell Death; Cerebral Hemorrhage; Collagenases; Deferoxamine; Fluorescent Antib | 2011 |
Improvement of rat islet viability during transplantation: validation of pharmacological approach to induce VEGF overexpression.
Topics: Adenoviridae Infections; Animals; Body Weight; Deferoxamine; Humans; Hypoxia-Inducible Factor 1, alp | 2011 |
Removal of cadmium by combining deferasirox and desferrioxamine chelators in rats.
Topics: Animals; Benzoates; Body Weight; Cadmium; Chelating Agents; Chelation Therapy; Deferasirox; Deferoxa | 2012 |
Desferrioxamine enhances AIDS-associated Kaposi's sarcoma tumor development in a xenograft model.
Topics: Acquired Immunodeficiency Syndrome; Animals; Apoptosis; Body Weight; Bromodeoxyuridine; Cell Divisio | 2002 |
Chelation therapy in acute iron poisoning.
Topics: Body Weight; Child; Child, Preschool; Deferoxamine; Humans; Infant; Iron | 1967 |
Experimental anemia induced by excess iron excretion.
Topics: Anemia, Hypochromic; Animals; Body Weight; Deferoxamine; Erythrocyte Count; Hemoglobins; Iron; Male; | 1980 |
Effects of subchronic desferrioxamine infusion on aluminum toxicity in rabbits.
Topics: Aluminum; Animals; Body Weight; Deferoxamine; Drinking; Eating; Injections, Subcutaneous; Male; Orga | 1984 |
Influence of hepatic artery occlusion and desferrioxamine on liver-tumour growth.
Topics: Adenocarcinoma; Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cell Divisi | 1995 |
Desferrioxamine treatment reduces histological evidence of lung damage in rats after acute nitrogen dioxide (NO2) intoxication.
Topics: Administration, Inhalation; Animals; Body Weight; Deferoxamine; Female; Injections, Intravenous; Lun | 1993 |
Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiomyopathies; Deferoxamine; Doxorubicin; Heart Rate; Injec | 1994 |
Assessment of the developmental toxicity of deferoxamine in mice.
Topics: Animals; Body Weight; Deferoxamine; Eating; Embryonic and Fetal Development; Female; Gestational Age | 1995 |
Novel protection strategy against X-ray-induced damage to salivary glands.
Topics: Animals; Body Weight; Deferoxamine; Male; Organ Size; Organometallic Compounds; Radiation-Protective | 1998 |
Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Blood Urea Nitrogen; Body Weight; Cochlea; Creatini | 1998 |
Effects of simultaneous administration of desferrioxamine and tacrine in rats.
Topics: Animals; Body Weight; Chelating Agents; Cholinesterase Inhibitors; Deferoxamine; Drug Synergism; Hea | 1998 |
Evidence for low molecular weight, non-transferrin-bound iron in rat brain and cerebrospinal fluid.
Topics: Aging; Animals; Binding Sites; Biological Transport; Blood-Brain Barrier; Body Weight; Brain; Defero | 1998 |
In vivo and in vitro iron deficiency reduces protein kinase C activity and translocation in murine splenic and purified T cells.
Topics: Anemia, Iron-Deficiency; Animals; Body Weight; CD3 Complex; Cell Division; Cell Membrane; Cells, Cul | 1999 |
Time course of changes in endothelium-dependent and -independent relaxation of chronically diabetic aorta: role of reactive oxygen species.
Topics: Acetylcholine; Amitrole; Animals; Aorta, Thoracic; Blood Glucose; Body Weight; Catalase; Chronic Dis | 2000 |
Effects of aminoguanidine and desferrioxamine on some vascular and biochemical changes associated with streptozotocin-induced hyperglycaemia in rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Chelating Agents; Deferoxamine; Drug Inte | 2001 |
Redox metal chelation ameliorates radiation-induced bone marrow toxicity in a mouse model.
Topics: Animals; Body Weight; Bone Marrow; Chelating Agents; Deferoxamine; Interleukin-6; Leukocyte Count; M | 2001 |
Linear growth in homozygous beta-thalassemia and beta-thalassemia/hemoglobin E patients under different treatment regimens.
Topics: beta-Thalassemia; Blood Transfusion; Body Height; Body Weight; Chi-Square Distribution; Child; Defer | 2001 |
Deferoxamine effect on selenite-induced cataract formation in rats.
Topics: Animals; Body Weight; Calcium; Cataract; Deferoxamine; Disease Models, Animal; Glutathione; Injectio | 1992 |
Antitumor effect of deferoxamine on human hepatocellular carcinoma growing in athymic nude mice.
Topics: Animals; Body Weight; Carcinoma, Hepatocellular; Deferoxamine; Drug Screening Assays, Antitumor; Hum | 1992 |
An ovine model of maternal iron poisoning in pregnancy.
Topics: Animals; Blood Pressure; Body Weight; Deferoxamine; Disease Models, Animal; Female; Ferric Compounds | 1990 |
Desferrioxamine-induced alterations in hepatic iron distribution, DNA damage and lipid peroxidation in control and 2,3,7,8-tetrachlorodibenzo-p-dioxin-treated rats.
Topics: Animals; Body Weight; Deferoxamine; DNA; DNA Damage; Female; Iron; Lipid Peroxidation; Liver; Organ | 1990 |
Deferoxamine injection does not affect bleomycin-induced lung fibrosis in rats.
Topics: Animals; Bleomycin; Body Weight; Collagen; Deferoxamine; Lung; Male; Organ Size; Pulmonary Fibrosis; | 1985 |
Deferoxamine therapy in high-ferritin diabetes.
Topics: Aged; Analysis of Variance; Blood Glucose; Body Weight; Cholesterol; Deferoxamine; Diabetes Mellitus | 1989 |
Effect of desferrioxamine on the development of hexachlorobenzene-induced porphyria.
Topics: 5-Aminolevulinate Synthetase; Animals; Body Weight; Carboxy-Lyases; Chlorobenzenes; Deferoxamine; Di | 1986 |
An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators.
Topics: Administration, Oral; Animals; Body Weight; Chelating Agents; Deferoxamine; Dihydropyridines; Ferrit | 1986 |
Storage iron exchange in the rat as affected by deferoxamine.
Topics: Anemia, Hemolytic; Animals; Body Weight; Chondroitin Sulfates; Deferoxamine; Feces; Ferritins; Half- | 1985 |
[Comparative studies on the efficacy of chelating agents in experimental iron storage disease in the rat].
Topics: Animals; Body Weight; Chelating Agents; Deferoxamine; Female; Hemochromatosis; Iron; Liver; Liver Ci | 1967 |
Effect of 1,10-phenanthroline and desferrioxamine in vivo on prolyl hydroxylase and hydroxylation of collagen in various tissues of rats.
Topics: Animals; Animals, Newborn; Body Weight; Calcium; Carrageenan; Collagen; Deferoxamine; Estradiol; Fem | 1974 |
The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
Topics: Administration, Oral; Animals; Ascorbic Acid; Benzoates; Blood Transfusion; Body Weight; Calcium; Ca | 1974 |
Management of thalassemia: a comparative program.
Topics: Adolescent; Asian People; Blood Transfusion; Body Height; Body Weight; Child; Child, Preschool; Defe | 1969 |
Hematological investigations in Ethiopia with special reference to a high iron intake.
Topics: Adolescent; Adult; Altitude; Anemia; Autopsy; Blood Sedimentation; Blood Specimen Collection; Body W | 1968 |
[DNase II activity and iron imbalance in guinea pig tissues].
Topics: Animals; Body Weight; Deferoxamine; Deoxyribonucleases; Depression, Chemical; Guinea Pigs; Iron; Iro | 1969 |